(UTI) Universal Technical - Ratings and Ratios
Technical,Trades, Automotive,Welding,Diesel
UTI EPS (Earnings per Share)
UTI Revenue
Description: UTI Universal Technical
Universal Technical Institute Inc (NYSE:UTI) is a common stock listed on the New York Stock Exchange, operating in the Education Services sub-industry. The companys market capitalization stands at $1.818 billion, indicating a mid-cap status.
The stocks valuation metrics suggest a relatively high price-to-earnings ratio of 31.92, which may indicate overvaluation or high growth expectations. The forward P/E ratio is slightly lower at 27.70, potentially signaling a decrease in earnings growth rate. Return on Equity (RoE) is 22.12%, indicating a decent return for shareholders. To further assess the companys performance, key drivers such as revenue growth, student enrollment numbers, and program offerings should be examined.
Key Performance Indicators (KPIs) for UTI may include student retention rates, graduate employment rates, and revenue per student. Economic drivers influencing the companys performance could be the demand for skilled technicians in the automotive and industrial industries, government policies on vocational training, and competition in the for-profit education sector. Analyzing these factors can provide insights into the companys future prospects and potential stock performance.
To evaluate the stocks potential, its essential to consider its beta of 1.585, indicating higher volatility compared to the overall market. This, combined with the stocks current price and moving averages, may suggest a potential trading range or trend reversal. A thorough analysis of the companys financials, management team, and industry trends is necessary to make an informed investment decision.
UTI Stock Overview
Market Cap in USD | 1,402m |
Sub-Industry | Education Services |
IPO / Inception | 2003-12-17 |
UTI Stock Ratings
Growth Rating | 83.1 |
Fundamental | 79.8% |
Dividend Rating | 4.42 |
Rel. Strength | 27.2 |
Analysts | 4.83 of 5 |
Fair Price Momentum | 27.24 USD |
Fair Price DCF | 4.42 USD |
UTI Dividends
Currently no dividends paidUTI Growth Ratios
Growth Correlation 3m | -86.9% |
Growth Correlation 12m | 86.3% |
Growth Correlation 5y | 86% |
CAGR 5y | 26.31% |
CAGR/Max DD 5y | 0.51 |
Sharpe Ratio 12m | 0.37 |
Alpha | 31.19 |
Beta | 1.058 |
Volatility | 67.29% |
Current Volume | 1387.3k |
Average Volume 20d | 624.9k |
Stop Loss | 24.3 (-6.6%) |
Signal | -0.55 |
Piotroski VR‑10 (Strict, 0-10) 7.5
Net Income (63.1m TTM) > 0 and > 6% of Revenue (6% = 48.6m TTM) |
FCFTA 0.10 (>2.0%) and ΔFCFTA 3.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
NWC/Revenue 0.02% (prev 0.40%; Δ -0.38pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
CFO/TA 0.15 (>3.0%) and CFO 107.8m > Net Income 63.1m (YES >=105%, WARN >=100%) |
Net Debt (187.6m) to EBITDA (115.9m) ratio: 1.62 <= 3.0 (WARN <= 3.5) |
Current Ratio 1.00 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
Outstanding Shares last Quarter (55.6m) change vs 12m ago 1.24% (target <= -2.0% for YES) |
Gross Margin 49.65% (prev 46.46%; Δ 3.19pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
Asset Turnover 111.9% (prev 100.1%; Δ 11.82pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
Interest Coverage Ratio 10.78 (EBITDA TTM 115.9m / Interest Expense TTM 6.99m) >= 6 (WARN >= 3) |
Altman Z'' 1.27
(A) 0.00 = (Total Current Assets 185.2m - Total Current Liabilities 185.0m) / Total Assets 740.8m |
(B) 0.11 = Retained Earnings (Balance) 82.8m / Total Assets 740.8m |
(C) 0.10 = EBIT TTM 75.3m / Avg Total Assets 723.4m |
(D) 0.19 = Book Value of Equity 83.8m / Total Liabilities 434.0m |
Total Rating: 1.27 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 79.77
1. Piotroski 7.50pt = 2.50 |
2. FCF Yield 5.44% = 2.72 |
3. FCF Margin 9.23% = 2.31 |
4. Debt/Equity 0.30 = 2.46 |
5. Debt/Ebitda 0.80 = 2.03 |
6. ROIC - WACC 5.11% = 6.39 |
7. RoE 22.12% = 1.84 |
8. Rev. Trend 90.65% = 4.53 |
9. Rev. CAGR 22.68% = 2.50 |
10. EPS Trend data missing |
11. EPS CAGR 32.43% = 2.50 |
What is the price of UTI shares?
Over the past week, the price has changed by -3.09%, over one month by -18.48%, over three months by -22.83% and over the past year by +49.77%.
Is Universal Technical a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of UTI is around 27.24 USD . This means that UTI is currently overvalued and has a potential downside of 4.65%.
Is UTI a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the UTI price?
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 37.6 | 44.4% |
Analysts Target Price | 37.3 | 43.4% |
ValueRay Target Price | 30.6 | 17.6% |
Last update: 2025-08-13 02:51
UTI Fundamental Data Overview
CCE Cash And Equivalents = 120.6m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 22.2069
P/E Forward = 25.3165
P/S = 1.7318
P/B = 4.7649
P/EG = 1.6893
Beta = 1.585
Revenue TTM = 809.5m USD
EBIT TTM = 75.3m USD
EBITDA TTM = 115.9m USD
Long Term Debt = 70.9m USD (from longTermDebt, last quarter)
Short Term Debt = 21.6m USD (from shortTermDebt, last quarter)
Debt = 92.5m USD (Calculated: Short Term 21.6m + Long Term 70.9m)
Net Debt = 187.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.37b USD (1.40b + Debt 92.5m - CCE 120.6m)
Interest Coverage Ratio = 10.78 (Ebit TTM 75.3m / Interest Expense TTM 6.99m)
FCF Yield = 5.44% (FCF TTM 74.7m / Enterprise Value 1.37b)
FCF Margin = 9.23% (FCF TTM 74.7m / Revenue TTM 809.5m)
Net Margin = 7.79% (Net Income TTM 63.1m / Revenue TTM 809.5m)
Gross Margin = 49.65% ((Revenue TTM 809.5m - Cost of Revenue TTM 407.6m) / Revenue TTM)
Tobins Q-Ratio = 16.40 (Enterprise Value 1.37b / Book Value Of Equity 83.8m)
Interest Expense / Debt = 1.51% (Interest Expense 1.39m / Debt 92.5m)
Taxrate = 25.30% (from yearly Income Tax Expense: 14.2m / 56.2m)
NOPAT = 56.3m (EBIT 75.3m * (1 - 25.30%))
Current Ratio = 1.00 (Total Current Assets 185.2m / Total Current Liabilities 185.0m)
Debt / Equity = 0.30 (Debt 92.5m / last Quarter total Stockholder Equity 306.8m)
Debt / EBITDA = 0.80 (Net Debt 187.6m / EBITDA 115.9m)
Debt / FCF = 1.24 (Debt 92.5m / FCF TTM 74.7m)
Total Stockholder Equity = 285.2m (last 4 quarters mean)
RoA = 8.52% (Net Income 63.1m, Total Assets 740.8m )
RoE = 22.12% (Net Income TTM 63.1m / Total Stockholder Equity 285.2m)
RoCE = 21.15% (Ebit 75.3m / (Equity 285.2m + L.T.Debt 70.9m))
RoIC = 14.48% (NOPAT 56.3m / Invested Capital 388.7m)
WACC = 9.37% (E(1.40b)/V(1.49b) * Re(9.91%)) + (D(92.5m)/V(1.49b) * Rd(1.51%) * (1-Tc(0.25)))
Shares Correlation 5-Years: 100.0 | Cagr: 10.63%
Discount Rate = 9.91% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 60.74% ; FCFE base≈63.9m ; Y1≈39.3m ; Y5≈15.7m
Fair Price DCF = 4.42 (DCF Value 240.7m / Shares Outstanding 54.4m; 5y FCF grow -44.57% → 3.0% )
Revenue Correlation: 90.65 | Revenue CAGR: 22.68%
Revenue Growth Correlation: -75.43%
EPS Correlation: N/A | EPS CAGR: 32.43%
EPS Growth Correlation: -4.33%
Additional Sources for UTI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle